CDC7 as a novel biomarker and druggable target in cancer

• Runze Liu ^[1] ; Yong Huang ^[1]
  1. [1] National Center for International Research of Bio-Targeting Theranostics, Guangxi Key Laboratory of Bio-Targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Bio-Targeting Theranostics, Guangxi Medical University, Nanning, 530021, Guangxi, China
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 10 (October), 2022, págs. 1856-1864
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Due to the bottlenecks encountered in traditional treatment for tumor, more effective drug targets need to be developed. Cell division cycle 7 kinase plays an important role in DNA replication, DNA repair and recombination signaling pathways. In this review, we first describe recent studies on the role of CDC7 in DNA replication in normal human tissues, and then we integrate new evidence focusing on the important role of CDC7 in replication stress tolerance of tumor cells and its impact on the prognosis of clinical oncology patients. Finally, we comb through the CDC7 inhibitors identified in recent studies as a reference for further research in clinical practice.